Related Experiment Video
Updated: Mar 31, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies
1Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. mosse@chop.edu.
Abstract:
In this era of more rational therapies, substantial efforts are being made to identify optimal targets. The discovery of translocations involving the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase in a subset of non-small cell lung cancers has become a paradigm for precision medicine. Notably, ALK was initially discovered as the fusion gene in anaplastic large cell non-Hodgkin lymphoma, a disease predominantly of childhood. The discovery of activating kinase domain mutations of the full-length ALK receptor as the major cause of hereditary neuroblastoma, and that somatically acquired mutations and amplification events often drive the malignant process in a subset of sporadic tumors, has established ALK as a tractable molecular target across histologically diverse tumors in which ALK is a critical mediator of oncogenesis. We are now uncovering the reexpression of this developmentally regulated protein in a broader subset of pediatric cancers, providing therapeutic targeting opportunities for diseases with shared molecular etiology. This review focuses on the role of ALK in pediatric malignancies, alongside the prospects and challenges associated with the development of effective ALK-inhibition strategies.
Insights
Anaplastic lymphoma kinase (ALK) is a key target in pediatric cancers. Targeting ALK offers new therapeutic opportunities for various childhood malignancies with shared molecular drivers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) was initially identified as a fusion gene in non-Hodgkin lymphoma.
- ALK's role has expanded beyond lymphoma to include non-small cell lung cancer and neuroblastoma.
- ALK is a developmentally regulated protein implicated in oncogenesis across diverse tumor types.
Purpose of the Study:
- To review the role of anaplastic lymphoma kinase (ALK) in pediatric malignancies.
- To explore therapeutic targeting opportunities for ALK-driven pediatric cancers.
- To discuss the prospects and challenges of ALK-inhibition strategies in pediatric oncology.
Main Methods:
- Literature review of ALK's role in pediatric cancers.
- Analysis of ALK's molecular mechanisms in oncogenesis.
- Examination of ALK-targeted therapies and their clinical implications.
Main Results:
- ALK is reexpressed in a broader subset of pediatric cancers, indicating therapeutic potential.
- ALK mutations and amplifications are critical drivers in various sporadic pediatric tumors.
- ALK serves as a tractable molecular target across histologically diverse pediatric malignancies.
Conclusions:
- Targeting anaplastic lymphoma kinase (ALK) presents significant therapeutic opportunities for pediatric cancers.
- Understanding ALK's role in oncogenesis is crucial for developing effective ALK-inhibition strategies.
- Further research is needed to overcome challenges in ALK-targeted therapy for pediatric malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:23Abnormal Proliferation
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...